Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249497 | 0.80 | PTPN1 (0.50) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL11299779 | 0.79 | NCEH1 (0.44) | ALDH1A1MEN1KMT2AHPGDHSD17B10 | |
| SCHEMBL9821944 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL25812222 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL29666490 | 0.73 | SIGMAR1 (0.67) | SIGMAR1NR4A1NR4A2NR4A3GAA | |
| SCHEMBL1614544 | 0.73 | SIGMAR1 (0.67) | SIGMAR1NR4A1NR4A2NR4A3GAA | |
| SCHEMBL27899644 | 0.73 | KMT2A (0.47) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL18503019 | 0.73 | KMT2A (0.47) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL20296817 | 0.73 | MEN1 (0.43) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL12048718 | 0.72 | PDE5A (0.42) | ALDH1A1MEN1KMT2AHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3538510-B1 | PROCESS FOR THE PREPARATION OF MONO-PROTECTED ALPHA,OMEGA-DIAMINO ALKANES | BYONDIS BV (NL) | 2021-01-06 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-2751076-B1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2018-04-25 | — | — | EP | claimed |
| EP-2550285-B1 | TRIOXACARCINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | claimed |
| EP-1833817-B1 | SYNTHESIS OF CCR5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-10-13 | — | — | EP | claimed |
| EP-1641754-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R, 2S, 5S)-3- AZABICYCLO[ 3, 1, 0]HEXANE-2-CARBOXAMIDE, N- [3-AMINO -1-(CYCLOBUTYLMETHYL)-2, 3-DIOXOPROPYL] ]-3- [ (2S)- 2-[[[1, 1-DIMETHYLETHYL ]AMINO]CARBONYLA MINO ]-3, 3-DIMETHYL-1-OXOBUTYL] -6, 6-DIMETHYL | SCHERING CORP (US) | 2008-03-26 | — | — | EP | claimed |
| EP-1436284-B1 | SYNTHESIS OF 4- (Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL]-1'- 2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL]-4'METHYL-1,4'BIPIPERIDINE | SCHERING CORP (US) | 2005-08-03 | — | — | EP | claimed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-118647614-A | Crystalline forms of N- (6-amino-5-methylpyridin-3-yl) -2- (benzo [ d ] thiazol-5-yl) -5-methylpiperidin-1-yl) -2-oxoacetamide, pharmaceutical compositions and methods of use | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | ALDH1A1 319/4885MEN1 171/4885KMT2A 4262/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | ALDH1A1 795/4885MEN1 1162/4885KMT2A 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.